BioMarin Q4 Revenue Beats by 5%, EPS Misses 16%, PTs $86–$104
Canaccord raised its price target on BioMarin to $104 from $98 and Bernstein lifted its target to $94 from $90, while Guggenheim cut its target to $86 from $106 after Q4 results. BioMarin reported $875 million revenue (5% beat) and $0.46 EPS (16% miss), with revenue guidance down 6%.
1. Analyst Price Target Revisions
Canaccord raised its price target to $104 from $98 and reiterated a Buy rating, while Bernstein lifted its target to $94 from $90 with an Outperform rating. Conversely, Guggenheim trimmed its target to $86 from $106 but maintained a Buy rating, reflecting diverging analyst views on BioMarin’s pipeline value.
2. Q4 Financial Performance
BioMarin reported $875 million in Q4 2025 revenue, surpassing consensus by 5%, driven by strong enzyme sales. However, diluted EPS of $0.46 fell 16% short of forecasts, largely reflecting an unmodeled write-down of its gene therapy asset Roctavian.
3. Guidance and Strategic Updates
The company lowered its full-year revenue guidance by 6% and EPS guidance by 3%, citing softness in its Voxzogo franchise. BioMarin also closed its acquisition of Amicus Therapeutics and continues to advance its pipeline candidates including valoctocogene roxaparvovec and Vosoritide.